{
    "name": "omega 3 fatty acids",
    "comment": "Rx",
    "other_names": [
        "Lovaza",
        "Vascazen",
        "Omtryg",
        "Omega-3-acid ethyl esters"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "Other",
        "Nutritionals",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/lovaza-omega-3-fatty-acids-342455",
    "pregnancy": {
        "common": [
            "Available data from published case reports and pharmacovigilance database on use in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development when given at doses 5 times maximum recommended human dose (MRHD) of 4 grams/day, based on a body surface area comparison; omega-3-acid ethyl esters given orally to rats and rabbits during organogenesis was not teratogenic at clinically relevant exposures, based on body surface area comparison"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Published studies have detected omega-3 fatty acids, including EPA and DHA, in human milk",
            "Lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk",
            "There are no data available on effects of omega- 3 fatty acid ethyl esters on breastfed infant or on milk production",
            "Developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinue medications that exacerbate hypertriglyceridemia",
                "Use caution in patients allergic to fish",
                "May increase liver ALT without increasing AST (monitor)",
                "May increase LDL levels (monitor)",
                "May prolong bleeding time (use caution)",
                "Recurrent AF or flutter observed when initial high dose of Lovaza administered (ie, 8 g/day x1 week, then 4 g/day thereafter)"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alteplase",
            "description": {
                "common": "omega 3 fatty acids, alteplase. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anagrelide",
            "description": {
                "common": "omega 3 fatty acids, anagrelide. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "omega 3 fatty acids, antithrombin alfa. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "omega 3 fatty acids, antithrombin III. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "omega 3 fatty acids, argatroban. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "omega 3 fatty acids, aspirin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "omega 3 fatty acids, aspirin/citric acid/sodium bicarbonate. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "omega 3 fatty acids, betrixaban.\nEither increases levels of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "omega 3 fatty acids, bivalirudin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "omega 3 fatty acids, clopidogrel. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "omega 3 fatty acids, dabigatran. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "omega 3 fatty acids, dalteparin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desirudin",
            "description": {
                "common": "omega 3 fatty acids, desirudin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "omega 3 fatty acids, dipyridamole. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "omega 3 fatty acids, enoxaparin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "omega 3 fatty acids, fondaparinux. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "omega 3 fatty acids, heparin. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "omega 3 fatty acids, prasugrel. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reteplase",
            "description": {
                "common": "omega 3 fatty acids, reteplase. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "omega 3 fatty acids, tenecteplase. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "omega 3 fatty acids, ticlopidine. Other (see comment). Use Caution/Monitor. \nComment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "omega 3 fatty acids, vorapaxar.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "omega 3 fatty acids, vortioxetine.\nEither increases effects of the other by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "omega 3 fatty acids increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "omega 3 fatty acids, zanubrutinib.\nEither increases effects of the other by anticoagulation. Modify Therapy/Monitor Closely. Zanubrutinib-induced cytopenias increases risk of hemorrhage. Coadministration of zanubritinib with antiplatelets or anticoagulants may further increase this risk."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Eructation",
            "percent": "4.9"
        },
        {
            "name": "Infection",
            "percent": "4.4"
        },
        {
            "name": "Flu",
            "percent": "3.5"
        },
        {
            "name": "like syndrome",
            "percent": "3.1"
        },
        {
            "name": "Dyspepsia",
            "percent": "2.7"
        },
        {
            "name": "Taste perversion",
            "percent": "2.2"
        },
        {
            "name": "Back pain",
            "percent": "1.8"
        },
        {
            "name": "Pain",
            "percent": "1.8"
        },
        {
            "name": "Rash",
            "percent": "1.3"
        },
        {
            "name": "Angina pectoris",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction",
            "percent": null
        },
        {
            "name": "Hemorrhagic diathesis",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        }
    ]
}